key: cord-0334642-orhwfvl7
authors: Lee, C. Y.; Shah, M. K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P. G.; Babady, N. E.; Greenbaum, B.; Kamboj, M.; Vardhana, S. A.
title: Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies
date: 2021-08-29
journal: nan
DOI: 10.1101/2021.08.25.21262417
sha: 64afc3049a9fe8a48d73619147a61375ac6dd4fd
doc_id: 334642
cord_uid: orhwfvl7

ABSTRACT Coronavirus disease 2019 (COVID-19) infection results in high mortality rates in patients with hematologic malignancies. Persistent and/or recurrent COVID-19 has not yet been demonstrated in this population. We identified patients with B-cell lymphomas as having a particularly high risk for persistent SARS-CoV-2 positivity. Subsequent analysis of patients with lymphoid malignancies and COVID-19 identified discrete risk factors for severity of primary infection as compared to disease chronicity. Active therapy and diminished T-cell counts were key drivers of acute mortality in lymphoma patients with COVID-19 infection. Conversely, B-cell depleting therapy was the primary driver of re-hospitalization for COVID-19. In patients with persistent SARS-CoV-2 positivity, we observed high levels of viral entropy consistent with intrahost viral evolution, particularly in patients with impaired CD8+ T-cell immunity. These results suggest that persistent COVID-19 infection is likely to remain a risk in patients with impaired adaptive immunity and that additional therapeutic strategies are needed to enable viral clearance in this high-risk population. Statement of Significance We establish persistent symptomatic COVID-19 infection as a novel clinical syndrome in patients with lymphoid malignancies and identify B-cell depletion as the key immunologic driver of persistent infection. Furthermore, we demonstrate ongoing intrahost viral evolution in patients with persistent COVID-19 infection, particularly in patients with impaired CD8+ T-cell immunity.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to chronic manifestations in healthy and immunocompromised individuals with different clinical presentations and unique risks. In otherwise healthy people hospitalized with coronavirus disease 2019 (COVID- 19) , up to one-third continue to experience physical and cognitive symptoms, a syndrome commonly referred to as long COVID. 1 In severely immunocompromised hosts, protracted respiratory symptoms with frequent readmissions can occur. The underlying pathogenic mechanisms for the two entities are not well understood. However, for severely immunocompromised patients, isolated cases of persistent COVID- 19 clinical manifestations with co-incident persistent respiratory SARS-CoV-2 RNA detection and the absence of seroconversion have been reported. 2, 3 Certain immunocompromising conditions, such as hematologic malignancy, are associated with a higher risk for severe COVID-19 and poor outcomes after acute infection. [4] [5] [6] The unusual and protracted disease course marked by intermittent flares is less defined but a frequently encountered COVID-19 complication in this patient population. Persons with lymphoid malignancy, especially those with diminished T-cell responses and after B-cell depleting therapies, are particularly susceptible. 7 A few case reports describe the clinical and viral genomic evolution in chronically infected patients with lymphoid malignancies and highlight the immunologic correlation with impaired CD4 and CD8 virusspecific T-cell responses. 3, 8 In addition to the substantial direct morbidity from COVID-19 and interruption in cancer care, chronic persistent SARS-CoV-2 infection poses the additional threat of extended transmissibility and selection pressure that could generate immune evading mutations. 8, 9 Intra-host evolution in chronic SARS-CoV-2 infection has led to the detection of mutations found in variants of concern (VOC), raising intense speculation that immunocompromised patients may serve as reservoirs for the emergence of critical mutations in the receptor binding domain (RBD) region of the virus. 8 Therefore, a better understanding of chronic infection in severely immunocompromised patients is significant from both a therapeutic and public health perspective. In the present study, we identify predictors of persistent COVID-19 among patients with hematologic malignancies and characterize the clinical course and viral genomic evolution in patients with lymphoid malignancy, including those receiving B-cell depleting therapies. Supplementary Table 1 and Table 1 , respectively. Receipt of systemic parenteral chemotherapy within 30 days, treatment with anti-CD20 antibodies within 1 year, and cellular therapy including hematopoietic stem cell transplantation (HSCT) within 1 year were independent predictors of prolonged SARS-CoV-2 RNA detection. Age and underlying lymphoid malignancy did not independently influence prolonged viral detection among patients with hematologic cancers.

Given that the strongest predictors of viral persistence are standard of care therapies for patients with lymphoid malignancies, we subsequently identified 214 patients with lymphoid malignancy and COVID-19 infection between March 2020 and January 2021 (Supplementary Table 2 The case fatality rate during the index hospitalization was 22%. Thirty-two patients (31%) experienced an extended hospitalization over 21 days, and 19 out of the remaining 77 patients who were discharged following index hospitalization were readmitted with recrudescent respiratory symptoms after initial improvement. Most of these patients had continuous COVID-19 PCR positivity, suggestive of a high rate of incomplete viral clearance in this population.

Univariate analysis identified clinical and laboratory features associated with death from acute COVID-19 infection, as shown in Figure 2a and Supplementary Figure 1a . Key predictors of death included cardiovascular illness, relapsed/refractory disease, and active treatment, including anti-CD20 and CAR T-cell therapy in the past year. Multivariate analysis revealed cardiovascular disease, active treatment, and CAR T-cell therapy, but not anti-CD20 therapy, to be independently associated with mortality.

Additionally, unbiased clustering of immunologic laboratory data obtained from patients during acute infection generated three semi-global clusters of patients with distinct immunologic phenotypes ( Figure   2b and Supplementary Figure 2) . Cluster 1 was defined by the most significantly reduced levels of Tcells as well as the lowest ratio of effector or activated T-cells to naïve T-cells, but the highest levels of acute inflammatory markers, consistent with a blunted T-cell response. Cluster 2 was defined by intermediate T-cell counts, a relatively high incidence of anti-CD20 therapy, and a relatively high level of T-cell activation as well as moderate levels of acute inflammatory markers, consistent with a partially compensated immune response in the presence of B-cell depletion. Finally, cluster 3 was defined by minimal acute inflammatory markers, normal T-cell counts, and higher levels of T-cell activation consistent with a sufficient adaptive immune response. Correlation of immune clusters with COVIDspecific clinical outcomes demonstrated the highest mortality in cluster 1 (5/11, 45%), the lowest mortality rate in cluster 3 (3/17, 18%), and intermediate mortality (3/8, 38%), but a high rate of readmission to the hospital for persistent symptomatic disease (4/8, 50%) in cluster 2.

We therefore asked whether specific inflammatory markers were associated with clinical outcomes in (Supplementary Figure 1b) . However, patients with either severe CD8 + lymphopenia (<50 cells/µL) or CD4 + lymphopenia (<100 cells/µL) had markedly poor outcomes (Figure 2d) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 29, 2021. ;

Given the high rate of persistent PCR positivity, protracted hospital stay and re-hospitalization in this population, we next asked whether distinct clinical or immunologic factors were associated with persistent COVID-19 infection. To uncouple factors associated with prolonged disease from factors associated with severe initial disease, we focused on the outcomes of patients whose COVID-19 was sufficiently severe to require hospitalization (n=102) to determine whether patients who died during their primary hospitalization (n=26), patients who were discharged and not re-admitted to the hospital (n=57), and patients who were re-admitted to the hospital for COVID-19-related symptomatology (n=19) exhibited distinct clinical and laboratory manifestations (Supplementary Figure 3a) . The clinical description of these 19 cases is presented in Table 2 . Table 2) . Five patients died during the follow-up period; four deaths were attributed to progressive respiratory decline due to symptomatic COVID-19 and one death was attributed to both progressive symptomatic COVID-19 and concurrent pulmonary coccidiomycosis.

Relapsed or refractory lymphoma and recent systemic therapy were independent predictors of hospital re-admission for symptomatic COVID-19, the strongest individual treatments of which were anti-CD20 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021 Figure 3b-c) . On multivariate analysis, only anti-CD20 therapy was independently associated with hospital readmission (HR 4.23, 95% CI 1.38-13.02) (Figure 3a-b) . Among the laboratory parameters, a decrease in CD4 + , but not CD8 + T-cells corelated with risk of re-admission (Figure 3c) . Notably, there was no significant difference in initial inflammatory markers between patients who were or were not rehospitalized for COVID-19 (Supplementary Figure 3d) . Taken together, this data indicates that immunosuppression, and in particular loss of B-and CD4 T-cell immunity driven at least in part by Bcell directed therapies, is a risk factor for persistent symptomatic COVID-19 infection and suggests that CD4 + T-cell and/or B-cell function may contribute to complete viral eradication. Consistent with this hypothesis, patients who were ultimately re-hospitalized for COVID-19 exhibited an increased proportion of activated CD4 + and CD8 + T-cells, suggesting ongoing active infection in these patients ( Figure 3C ).

Viral evolution, reinfection, and immune escape have been described in immunocompromised patients with COVID-19 infection. 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint Finally, we computed the viral entropy, as defined in the Methods, across variant allele frequencies of all mutations which differed from the reference sequence, with a higher entropy indicating greater heterogeneity in the viral population. We observed higher viral entropy in patients with impaired CD8 + T-cell counts, but not in patients who had received anti-CD20 therapy in the past year (Figure 4b) ,

suggesting that viral diversity may be constrained by an active CD8 + T-cell immune population and patients who harbor higher viral diversity during chronic infection have weaker adaptive responses.

The unique contribution of this report is the description of persistent symptomatic COVID-19 in patients with lymphoid malignancy, a condition predisposed by previous anti-CD20 therapy and observed in 21% of anti-CD20 treated patients in our cohort. The syndrome manifests as a chronic protracted illness marked by slowly progressive or relapsing respiratory illness with progressive lower airway changes on CT imaging and persistent viral RNA detection. This complication affected 19/76 hospitalized patients with initial improvement and resulted in delay of cancer-directed therapy for 13/19 patients; 4/19 eventually died from the direct long-term sequelae of chronic COVID-19 infection. At a virologic level, we did not find any evidence of reinfection or co-infection with reactivation. Intra-host evolution of the virus suggested ongoing replication. Our analysis points to immune dysregulation characterized by combined loss of B-cell function and impaired CD4 + T-cell counts (CD4 <100 cells/µL) and compensatory innate immune and CD8 + T-cell activation as the basis for this chronic syndrome.

Multiple studies thus far have established a high mortality rate in cancer patients with acute COVID-19 infection 4,6,10,11 ; the mechanistic explanations for this increased mortality rate have not been fully elucidated but may involve immune dysregulation and decreased functional status. The toxicity from COVID-19 infection clearly extends beyond the period of acute viral infection; the so-called "long COVID" syndrome is still an area of active exploration but is thought to be largely due to sequelae from prior infection rather than ongoing active infection. 12, 13 We had previously reported the presence of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint persistent PCR positivity with associated culturable virus in HSCT recipients lasting up to 3 months following initial COVID-19 infection. [14] [15] [16] [17] [18] We now describe chronic persistent COVID-19 infection as a separate clinical entity in a significant proportion of hematologic malignancy patients and identify unique clinical and virologic characteristics associated with this syndrome. The immunologic factors associated with death during acute severe COVID-19 infection among heme cancer patients include increased acute phase reactants, decreased CD4 + and CD8 + lymphopenia and limited diversity in T-cell responses. These deficits are distinct from those observed in chronic SARS-CoV-2 infection, which is characterized by CD4 + lymphopenia and Bcell aplasia. Furthermore, the immune profile risk is also different from prolonged infection in immunocompromised patients with other severe respiratory virus illnesses such as influenza and respiratory syncytial virus where the extent of cell mediated immunosuppression drives viral persistence and is almost exclusively observed after HSCT. 19, 20 Overall, our findings suggest that distinct arms of the immune response play dominant roles in controlling acute infection due to a novel virus and influence permanent SARS-CoV-2 viral clearance. 21-24 B-cell depletion due to anti-CD20 antibody therapy has been associated with viral persistence and reactivation especially in chronically infected hepatitis B patients following chemoimmunotherapy and an elevated risk of progressive multifocal leukoencephalopathy, herpes simplex virus and varicella-zoster virus has also been reported, but an association with prolonged viral shedding from respiratory viruses had yet to be described. 25, 26 The role of CD4 + T-cell depletion in viral persistence is less clear. CD4 + T-cell help is critical for both Bcell maturation and optimal CD8 + T-cell survival and function 27 ; conversely B-cell depletion may impair naïve CD4 + T-cell homeostasis. 28 Interestingly, greater intra-host viral diversity was observed mainly in patients with impaired CD8 + T-cell immunity. This may reflect greater evolution in the setting of partial immunity, as has been reported previously. 16 Whether B-cell depletion alters the COVID-19-reactive CD8 + T-cell repertoire is an area of ongoing investigation.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ;  There are several limitations in our present study. Laboratory markers, including flow cytometry data and viral sampling, were ordered at the discretion of the treating physician and were therefore not uniformly available across patients. Additionally, viral viability was not assessed in patients with persistent COVID-19 PCR positivity. Finally, the management of these patients was heterogeneous and physician dependent with rapidly emerging evidence. Despite this, the high volume of patients with hematologic malignancy and immune-depleting therapies at our institution enabled the identification of this novel syndrome.

In summary, the results of this work have significant implications for devising effective preventive and treatment strategies for COVID-infected patients with lymphoid malignancies. The high risk for adverse outcomes with acute COVID-19 in patients with lymphoid cancers is well recognized in multiple previous reports. 7, 29 We corroborate this finding among our large study cohort. Most importantly, we demonstrate the substantial morbidity and mortality associated with the long-term effects of chronic COVID-19 infection in lymphoma patients unable to attain adequate viral clearance and potentially posing a transmission risk to others. Future studies should elucidate the immunologic defects associated with this clinical phenomenon beyond the recent anti-CD20 treatment risk identified in our report. When taken in conjunction with emerging evidence on suboptimal COVID-19 vaccine response in anti-CD20 treated patients, 30-33 our findings urge for prioritization of passive immunoprophylactic approaches in high-risk patients with lymphoid malignancy. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint Technologies (IDT), Coralville, IA). Following cDNA synthesis and multiplexed PCR, libraries were prepared for the two amplicons pools using the Nextera XT DNA kit followed by sequencing on an Illumina Miseq platform (Illumina, San Diego, CA USA) as paired-end (2 × 150 base pair reads). We mapped the reads using STAR (version 2.7.7a) to the combined human (hg38 p.13, gencode release 36) and reference SARS-CoV-2 (NC_045512) genome 35 . Duplicates were removed using picard (version 2.24.2). 36 Reads were subset to those mapping to the viral genome and subsequently postprocessed as follows: first, ends of the reads were trimmed until the 10 bases closest to the end mapped to the reference with no mismatches. After that, the trimmed reads with overall identity to the reference less than 95% and reads shorter than 40 base pairs were discarded. In addition to that, if there were two mismatches to the reference within 5 bases of each other, the quality score for the corresponding bases was set to 2. After that the reads were written to FASTQ format and mapped to the SARS-CoV-2 genome using bwa (version 0.7.17-r1188). 37, 38 Single nucleotide variants (SNVs) were called using exactSNP program from the Subread package (v 2.0.0). 39 When we encountered major variants with respect to the reference genome, we applied those variants and reran SNV calling with the updated reference. Settings which we modified from the default for SNV calling are -Q 7 -n 2 -s 20 -T 5. We increased the default p-value cutoff (changed the -Q parameter from the default value of 12 to 7) to account for the fact that the size of the SARS-CoV-2 genome is 10 5 times smaller than the size of the human genome defaults are targeted at. When calling minor variants, we required the depth of coverage to be at least 50.

Consensus sequences of the viral genomes were assembled using bcftools. 40 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint where p a is the frequency of the minor allele at the site a. The total "viral entropy" per sequencing sample is the sum across the sites within that sample. This ignores the possible correlation between the polymorphic sites (i.e., minor variants observed at sites A and B can be present in the same clone or in two different clones), which generally cannot be determined using the short reads. On a perpatient basis, we utilized the sample viral entropy corresponding to the latest time point. Categorical tests were conducted using SciPy's ttest_ind function. 43 Linear and rank correlations to flow cytometry data were determined using SciPy's pearsonr and spearmanr functions. Portability and Accountability Act waiver of authorization to conduct this study. Clinical data were abstracted from the electronic medical record into standardized case report forms. Clinical laboratory . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint data were abstracted from the date closest to research blood collection. In addition to standard laboratory analyses performed on patients during acute COVID-19 infection, inflammatory markers including C-reactive protein, interleukin-6, D-dimer, ferritin, fibrinogen, and lactate dehydrogenase were measured in most inpatients. In addition, 8-color peripheral blood cytometry for annotation of T, B, and NK cell subsets was performed in 54.7% of hospitalized patients and 12-color peripheral blood flow cytometry for T-cell subset analysis was performed in 38.4%.

Descriptive statistics were used to summarize the data. Continuous variables were presented as means and standard deviations or as medians and ranges, as appropriate, and categorical variables were presented as counts and percentages. Overall survival (OS) was measured from the date of laboratory-confirmed COVID-19 to last follow-up or death. Data were censored on April 3, 2021. The probability of OS was estimated using the Kaplan-Meier method and differences compared using the log-rank test. Cox proportional hazard regression models were used to identify predictors of OS. Multivariate analysis using Cox proportional hazards model was used to identify the potential independent effects of those factors that attained a p-value of 0.1 in the univariate analysis. Vienna, Austria). Exact methods were used to calculate confidence intervals for the rate ratios. P values were calculated with the use of two-sided exact tests; a P value of less than 0.05 was considered to indicate statistical significance.

To determine whether there were distinct immunological responses to COVID-19 in our patient population, we identified 36 patients in whom at least 10% of laboratory analyses were performed and imputed missing data in these patients with the median of each feature (Figure 2b) . We projected the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint multivariate laboratory data by conducting a Uniform Manifold Approximation and Project (UMAP) in two dimensions (Supplementary Figure 2a) . 44 Next, we computed the Earth Mover's Distance (EMD) of each point in UMAP space to each other point. 45 We clustered these distances and identified three clusters based on immunologic laboratory markers alone.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.25.21262417 doi: medRxiv preprint

Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Prolonged Severe Acute Respiratory Syndrome

Coronavirus 2 Replication in an Immunocompromised Patient

Determinants of COVID-19 disease severity in patients with cancer

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

SARS-CoV-2 evolution during treatment of chronic infection

Replication in a CAR-T-cell Therapy Recipient: A Case Study

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Attributes and predictors of long COVID

Post-acute COVID-19 syndrome

Persistent COVID-19 Pneumonia and Failure to

Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Shedding of Viable SARS-CoV-2 after

Immunosuppressive Therapy for Cancer

Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient

Long-Term Shedding of Influenza Virus

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B

Facultative role of germinal centers and T cells in the somatic diversification of IgVH genes

Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients

Performance of Severe Acute Respiratory Syndrome

Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples

STAR: ultrafast universal RNA-seq aligner

Improving SNP discovery by base alignment quality

Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data

Twelve years of SAMtools and BCFtools

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

SciPy 1.0: fundamental algorithms for scientific computing in Python

UMAP: Uniform Manifold Approximation and